Evidence map›Paper›PMID 32231537›Full record

ArticleCase reports in oncology

Rituximab Twice Weekly for Refractory Thrombotic Thrombocytopenic Purpura in a Critically Ill Patient with Acute Respiratory Distress Syndrome.

Bahjat Azrieh, Arwa Alsaud, Khaldun Obeidat, Amr Ashour, Seham Elebbi, Shehab F Mohamed, Mohamed Adel Abdelaty, Abdelraouf Akkari, Abdurrahman Ali Elbuzidi, Mohamed A Yassin

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Bahjat AzriehDepartment of Medical Education, Hamad Medical Corporation, Doha, Qatar.
Arwa AlsaudDepartment of Medical Education, Hamad Medical Corporation, Doha, Qatar.
Khaldun ObeidatDepartment of Medical Education, Hamad Medical Corporation, Doha, Qatar.
Amr AshourDepartment of Medical Education, Hamad Medical Corporation, Doha, Qatar.
Seham ElebbiDepartment of Medical Education, Hamad Medical Corporation, Doha, Qatar.
Shehab F MohamedNational Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
Mohamed Adel AbdelatyNational Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
Abdelraouf AkkariNational Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
Abdurrahman Ali ElbuzidiNational Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
Mohamed A YassinNational Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar.
Hamad Medical Corporation · QANational Center for Cancer Care and Research · QA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thrombotic thrombocytopenic purpura (TTP) is a rare, serious, life-threatening disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, and hypercoagulability. The etiology is a deficiency of ADAMTS13 which is usually caused by acquired antibodies. Plasma exchange and steroids is the standard of care in the treatment of TTP. However, there are refractory cases of TTP which require further management. Rituximab appears to be a safe and effective therapy for refractory and relapsing TTP. Here we report a challenging case of TTP that responded to treatment with rituximab twice weekly. According to our knowledge, rituximab twice weekly has never been used for TTP before.

Indexed as

Platelet disorderRefractory diseaseRelapseRituximabThrombocytopeniaThrombotic thrombocytopenic purpura

Identifiers

PMID32231537
PMCPMC7098356
OpenAlexW3008463185

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.